Overview of the Investigation

The Rosen Law Firm, a prominent global legal firm specializing in investor rights, is actively investigating potential securities class action claims on behalf of shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO). This investigation follows allegations suggesting that Zenas BioPharma may have provided the investing public with materially misleading information about its business operations.

Potential Impact on Investors

Shareholders of Zenas BioPharma who acquired shares may qualify for compensation under a proposed class action. Notably, no upfront costs will be incurred, thanks to a contingency fee arrangement that allows for compensation based on any recovery achieved. The legal team at Rosen Law Firm is poised to pursue this class action aimed at recuperating losses for investors.

How to Participate in the Class Action

Investors who wish to be included in the potential class action are encouraged to take the following steps:

• Visit the Rosen Law Firm submission form.
• Contact Phillip Kim, Esq. by calling 866-767-3653 (toll-free).
• Email inquiries to ca**@********al.com for further details.

Why Choose Rosen Law Firm?

The Rosen Law Firm has a notable track record in representing investors, particularly in securities class actions. The firm has achieved significant settlements in the past, including the largest settlement ever against a Chinese company at that time. Their accolades also include:

• Ranked No. 1 by ISS Securities Class Action Services for the number of class action settlements in 2017.
• Top 4 ranking consistently since 2013.
• Recovery of hundreds of millions of dollars for investors, including over $438 million in 2019 alone.

Founding partner Laurence Rosen has received recognition as a leader in the plaintiffs’ bar, adding to the firm’s credibility in the legal landscape.

Stay Connected

To keep updated on this investigation and related news, follow the Rosen Law Firm on their social platforms:

• LinkedIn
• Twitter
• Facebook